Global Patent Index - EP 2195002 A4

EP 2195002 A4 20110907 - ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES

Title (en)

ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES

Title (de)

ERYTHROPOETIN-REZEPTOR-PEPTID-FORMULIERUNGEN UND VERWENDUNGEN

Title (fr)

FORMULATIONS DE PEPTIDE DE RÉCEPTEUR D'ÉRYTHROPOÏÉTINE ET UTILISATIONS

Publication

EP 2195002 A4 20110907 (EN)

Application

EP 08796513 A 20080723

Priority

  • US 2008070943 W 20080723
  • US 95739607 P 20070822
  • US 98975807 P 20071121

Abstract (en)

[origin: WO2009025957A1] The present invention relates to novel uses of peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to methods of usings such peptide compounds to treat disorders associated with insufficient or defective red blood cell production, including chemotherapy induced anemia. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. Also provided are kits and articles of manufacture comprising such compounds.

IPC 8 full level

A61K 38/16 (2006.01); A61K 38/17 (2006.01); A61K 47/48 (2006.01); A61P 7/06 (2006.01); C07K 14/505 (2006.01)

CPC (source: EP)

A61K 47/60 (2017.07); A61P 7/06 (2017.12); A61P 13/12 (2017.12); A61P 35/00 (2017.12); C07K 14/4705 (2013.01); A61K 38/00 (2013.01)

Citation (search report)

  • [XY] WO 2006133144 A2 20061214 - AFFYMAX INC [US], et al
  • [X] WO 2004101606 A2 20041125 - AFFYMAX INC [US], et al
  • [Y] US 2007027074 A1 20070201 - HOLMES CHRISTOPHER P [US], et al
  • [Y] GLASPY J A: "THE DEVELOPMENT OF ERYTHROPOIETIC AGENTS IN ONCOLOGY", EXPERT OPINION ON EMERGING DRUGS, ASHLEY PUBLICATIONS, GB, vol. 10, no. 3, 1 January 2005 (2005-01-01), pages 553 - 567, XP008074550, ISSN: 1472-8214
  • [Y] FAN ET AL: "Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia", EXPERIMENTAL HEMATOLOGY, NEW YORK, NY, US, vol. 34, no. 10, 1 October 2006 (2006-10-01), pages 1303 - 1311, XP005656813, ISSN: 0301-472X
  • [Y] WOODBURN ET AL: "Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model", EXPERIMENTAL HEMATOLOGY, NEW YORK, NY, US, vol. 35, no. 8, 26 July 2007 (2007-07-26), pages 1201 - 1208, XP022171067, ISSN: 0301-472X
  • [Y] REDDY G K ET AL: "Preliminary results of a phase II dose-finding study of subcutaneous Hematide(TM) in patients with cancer receiving chemotherapy", SUPPORTIVE CANCER THERAPY 200701 US, vol. 4, no. 2, January 2007 (2007-01-01), pages 74 - 75, XP001539117, ISSN: 1543-2912
  • See references of WO 2009025958A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2009025957 A1 20090226; EP 2195002 A1 20100616; EP 2195002 A4 20110907; JP 2010536857 A 20101202; JP 2010536858 A 20101202; WO 2009025958 A1 20090226

DOCDB simple family (application)

US 2008070926 W 20080723; EP 08796513 A 20080723; JP 2010521912 A 20080723; JP 2010521913 A 20080723; US 2008070943 W 20080723